In light of the encouraging results from our preclinical investigations, we decided to pioneer the use of [89Zr]Zr-PSMA-DFO for PET imaging in prostate cancer patients experiencing biochemical recurrence. This evidence concerns the gene FOLH1 and Familial prostate cancer.